Martek to Announce Second Quarter 2010 Results

COLUMBIA, Md., May 18 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that it intends to release the results of its second quarter of fiscal 2010 on June 2, 2010, at approximately 4:00 p.m. Eastern Time (ET).  At 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors.  All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.

An archived webcast of the conference call will be available on the Martek's website for thirty days.  In addition, a recorded playback of the call will be available for one week and can be accessed by calling 800-633-8284 or 402-977-9140 and entering pass code 21469921.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation, development, production and sales of high-value products from microbial sources that promote health and wellness through nutrition. The company is the world's leading provider of algal DHA omega-3 with its flagship product, life'sDHA™, a sustainable and vegetarian source of algal DHA omega-3 important for brain, heart and eye health throughout life, for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing up milks. Additionally, Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products in major mass, club, drug, grocery and specialty stores and holds leading brand positions in all of its key product categories. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA(TM) or life'sARA(TM) products, visit http://www.lifesdha.com/. For more information about Amerifit Brands, visit www.amerifit.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:	Kyle Stults
	Investor Relations
	[phone]
	Cassie France-Kelly
	Public Relations
	[phone]

SOURCE Martek Biosciences Corporation

Copyright y 18 PR Newswire